2. Nuvation Bio Inc. (NYSE:NUVB)
Cancer-Drug Sales Give the Pipeline a Commercial Foundation
Nuvation Bio Inc. (NYSE: NUVB) has progressed beyond a development-only oncology story. Its marketed treatment IBTROZI, or taletrectinib, generated $23.2 million in second-quarter 2026 net product revenue, up 25% sequentially. Total quarterly revenue reached $31.7 million.
That commercial foundation matters. Investors can now evaluate prescribing adoption and sales performance alongside the development pipeline, which includes investigational safusidenib for IDH1-mutant gliomas.
In its August update, Nuvation reported an FDA target action date of January 4, 2027, for a supplemental application containing updated IBTROZI efficacy data. That milestone concerns an already marketed medicine, rather than its initial approval.
The financial challenge remains substantial. Its quarterly net loss was approximately $62.8 million, demonstrating that growing sales have not yet covered the cost of running and developing the business.
Ranking rationale
Nuvation takes second place because IBTROZI’s commercial adoption provides measurable progress alongside its oncology pipeline. It ranks above Wave for having an established product revenue stream, but substantial losses and reliance on one marketed medicine limit its position. Sustained prescribing growth and spending discipline remain essential.
